Evaluation of Oleoylethanolamide supplementation in the prevention and treatment of non-alcoholic fatty liver disease
- Conditions
- on-alcoholic fatty liver disease.Fatty (change of) liver, not elsewhere classifiedK76.0
- Registration Number
- IRCT20110530006652N2
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 74
Age between 20 to 50 years old
Body mass index (BMI) of 30 to 40 Kg/m2
Diagnosis of non-alcoholic fatty liver disease by a radiologist based on ultrasonography
Regular use of non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics and corticosteroids
Use of hormonal drugs, hepatotoxic drugs (such as Phenytoin, Amiodarone, Levothyroxine, Tamoxifene and Lithium), anti-hypertensive drugs, weight loss and lipid lowering drugs
Use of prebiotic and probiotic supplements, vitamins, minerals, antioxidants, and omega 3 supplements
Diagnosed pathological conditions affecting the liver such as liver transplantation, acute or chronic hepatic impairment, viral hepatitis, cystic fibrosis, Haemochromatosis, Wilson's disease, Alpha-1 antitrypsin deficiency, and acute systemic disease
Diagnosed thyroid disorders
Diagnosed kidney diseases
Diagnosed gastrointestinal diseases (e.g. Celiac disease)
Diagnosed diabetes
Diagnosed heart failure
Diagnosed autoimmune diseases
Diagnosed malignancies
Diagnosed severe psychological disorders
Pregnancy and lactation
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method